AI-generated analysis. Always verify with the original filing.
Zenas BioPharma reported financial results for the quarter and year ended December 31, 2025, with net loss of $240.4 million and $377.7 million, respectively, cash and equivalents of $360.5 million, and secured up to $250 million non-dilutive debt financing from Pharmakon. The company announced plans for obexelimab BLA submission to FDA in Q2 2026 following positive Phase 3 INDIGO results.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 16, 2026, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on March 16, 2026 104 Cover Page Interactive Da
| Metric | Value | Basis |
|---|---|---|
| Revenue | $10.00 | |
| Research and development expenses | $55.70 | |
| Research and development expenses | $168.10 | |
| General and administrative expenses | $15.60 | |
| General and administrative expenses | $53.30 | |
| Acquired in-process research and development expenses | $166.70 | |
| Acquired in-process research and development expenses | $171.70 | |
| Net loss | $240.40 | |
| Net loss | $377.70 |
Debt / Financing